148 related articles for article (PubMed ID: 27558961)
1. The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition.
Zheng J; Zhao S; He X; Zheng Z; Bai W; Duan Y; Cheng S; Wang J; Liu X; Zhang G
Biochem Biophys Res Commun; 2016 Nov; 480(4):508-514. PubMed ID: 27558961
[TBL] [Abstract][Full Text] [Related]
2. LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing.
Deng H; Gao J; Cao B; Qiu Z; Li T; Zhao R; Li H; Wei B
Cell Oncol (Dordr); 2023 Dec; 46(6):1675-1690. PubMed ID: 37354353
[TBL] [Abstract][Full Text] [Related]
3. [Long intergenic non-coding RNA 01121 promotes metastasis of prostate cancer cells by activating the EMT process].
Wu J; Hua LX; Liu FD
Zhonghua Nan Ke Xue; 2022 Jun; 28(6):483-488. PubMed ID: 37477463
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of long non-coding RNA colon cancer-associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer.
Zhang J; Jiang Y; Zhu J; Wu T; Ma J; Du C; Chen S; Li T; Han J; Wang X
Oncol Lett; 2017 Dec; 14(6):6907-6914. PubMed ID: 29181105
[TBL] [Abstract][Full Text] [Related]
5. AAT resistance-related AC007405.2 and AL354989.1 as novel diagnostic and prognostic markers in prostate cancer.
Deng Y; Zhang C; Yu H; Chen G; Peng X; Li Y; Feng Z; Shi W; Bai X; Gou X; Liu N
Aging (Albany NY); 2024 Apr; 16(8):7249-7266. PubMed ID: 38643469
[TBL] [Abstract][Full Text] [Related]
6. Differential analysis of histopathological and genetic markers of cancer aggressiveness, and survival difference in EBV-positive and EBV-negative prostate carcinoma.
Ahmed K; Sheikh A; Fatima S; Ghulam T; Haider G; Abbas F; Sarria-Santamera A; Ghias K; Mughal N; Abidi SH
Sci Rep; 2024 May; 14(1):10315. PubMed ID: 38705879
[TBL] [Abstract][Full Text] [Related]
7. Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer.
Wan X; Huang W; Yang S; Zhang Y; Pu H; Fu F; Huang Y; Wu H; Li T; Li Y
Oncotarget; 2016 Sep; 7(37):60503-60518. PubMed ID: 27556357
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNAs CCAT1 and CCAT2 in colorectal liver metastases are tumor-suppressive via MYC interaction and might predict patient outcomes.
Franz C; Wuehrl M; Hartmann S; Klupp F; Schmidt T; Schneider M
PLoS One; 2023; 18(6):e0286486. PubMed ID: 37347737
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer.
Li Y; Fang Z; Ge S; Li J; Qu L; Shi X; Zhang W; Sun Y; Ren S; Wang L
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7305-7317. PubMed ID: 36920562
[TBL] [Abstract][Full Text] [Related]
10. LncRNA SNHG1 and RNA binding protein hnRNPL form a complex and coregulate CDH1 to boost the growth and metastasis of prostate cancer.
Tan X; Chen WB; Lv DJ; Yang TW; Wu KH; Zou LB; Luo J; Zhou XM; Liu GC; Shu FP; Mao XM
Cell Death Dis; 2021 Feb; 12(2):138. PubMed ID: 33542227
[TBL] [Abstract][Full Text] [Related]
11. Serine/threonine kinase 36 induced epithelial-mesenchymal transition promotes docetaxel resistance in prostate cancer.
He T; Li NX; Pan ZJ; Zou ZH; Chen JC; Yu SZ; Lv F; Xie QC; Zou J
Sci Rep; 2024 Jan; 14(1):729. PubMed ID: 38184689
[TBL] [Abstract][Full Text] [Related]
12. The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus.
Sakurai K; Reon BJ; Anaya J; Dutta A
Mol Cancer Res; 2015 May; 13(5):828-38. PubMed ID: 25700553
[TBL] [Abstract][Full Text] [Related]
13. A review of linc00673 as a novel lncRNA for tumor regulation.
Zhu K; Gong Z; Li P; Jiang X; Zeng Z; Xiong W; Yu J
Int J Med Sci; 2021; 18(2):398-405. PubMed ID: 33390809
[TBL] [Abstract][Full Text] [Related]
14. LncRNA TYMSOS is a novel prognostic biomarker associated with immune infiltration in prostate cancer.
Xia Z; Wu J; Li Y; Yuan X; Sun J; Lv C; Huang P
Am J Cancer Res; 2023; 13(10):4531-4546. PubMed ID: 37970350
[TBL] [Abstract][Full Text] [Related]
15. Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients.
Feng D; Li L; Li D; Wu R; Zhu W; Wang J; Ye L; Han P
Eur J Med Res; 2023 Jul; 28(1):245. PubMed ID: 37480146
[TBL] [Abstract][Full Text] [Related]
16. Updated review on analysis of long non-coding RNAs as emerging diagnostic and therapeutic targets in prostate cancers.
Ke Z; Hu X; Liu Y; Shen D; Khan MI; Xiao J
Crit Rev Oncol Hematol; 2024 Apr; 196():104275. PubMed ID: 38302050
[TBL] [Abstract][Full Text] [Related]
17. Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach.
De Summa S; Palazzo A; Caputo M; Iacobazzi RM; Pilato B; Porcelli L; Tommasi S; Paradiso AV; Azzariti A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672425
[TBL] [Abstract][Full Text] [Related]
18. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer-associated transcript 6 (PCAT6) promotes epithelial-mesenchymal transition and stemness and worsens prognosis in patients with colorectal cancer.
Sun X; Yuan Y; Li S; Gan L; Xu M; Li Q; Liu M; Hu K; Nan K; Zhang J; Dong Y; Lin Y; Zhang X; Hou P; Liu T
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; ():. PubMed ID: 38606479
[TBL] [Abstract][Full Text] [Related]
20. The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer.
Friedrich M; Wiedemann K; Reiche K; Puppel SH; Pfeifer G; Zipfel I; Binder S; Köhl U; Müller GA; Engeland K; Aigner A; Füssel S; Fröhner M; Peitzsch C; Dubrovska A; Rade M; Christ S; Schreiber S; Hackermüller J; Lehmann J; Toma MI; Muders MH; Sommer U; Baretton GB; Wirth M; Horn F
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32365858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
